Nuvectis Pharma is making strides in its clinical development programs, particularly with NXP800, a treatment for ARID1a-mutated ovarian cancer resistant to platinum-based chemotherapy. Recent findings from a Phase 1b study reveal promising antitumor activity, offering hope for patients with limited treatment options. The company also received Fast Track and Orphan Drug Designations from the FDA for NXP800, potentially accelerating its path to market.
NXP800 Shows Antitumor Activity in Phase 1b Trial
The Phase 1b study of NXP800 demonstrated encouraging results in patients with ARID1a-mutated ovarian cancer who had developed resistance to platinum-based chemotherapy. The trial reported one patient exhibiting an unconfirmed partial response and six patients achieving stable disease accompanied by tumor shrinkage. Furthermore, an adjusted intermittent dosing schedule reduced the severity of thrombocytopenia to Grade 2 in subsequent patients, enhancing the tolerability of the treatment.
FDA Grants Fast Track and Orphan Drug Designations
The FDA has granted both Fast Track and Orphan Drug Designations to NXP800 for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. These designations provide Nuvectis Pharma with incentives for drug development and the potential for up to seven years of market exclusivity upon approval. This regulatory support underscores the unmet medical need in this patient population and the potential of NXP800 to address it.
Advancing NXP900 Targeting SRC Family of Kinases
In addition to NXP800, Nuvectis Pharma is also developing NXP900, a drug targeting the SRC Family of Kinases. NXP900 is currently in a Phase 1a dose escalation study. The company plans to increase dose intensity in future cohorts and anticipates sharing additional clinical data in the second quarter of 2025. This ongoing research highlights Nuvectis Pharma's commitment to expanding its pipeline and addressing various cancer targets.
